Counseling Patients With oHCM––Using Data to Instill Confidence

This section focuses on educating patients about the specific pathophysiology of obstructive hypertrophic cardiomyopathy (oHCM), emphasizing how it differs from general HCM through the use of targeted cardiac myosin inhibitors such as mavacamten. Pharmacists are encouraged to explain the mechanism of action, which involves inhibiting excessive myosin-actin cross-bridge formation to reduce hypercontractility and improve diastolic relaxation. By leveraging extensive real-world Risk Evaluation and Mitigation Strategy data from over 11,000 patients spanning approximately 3 years, clinical pharmacists can instill confidence in the long-term safety and efficacy of the treatment, especially as real-world outcomes have proven consistent with or superior to original clinical trial results.